Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 5;10(5):e05766.
doi: 10.1002/ccr3.5766. eCollection 2022 May.

Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)

Patrick P Hess  1   2 , Monica S Ventura Ferreira  1   2 , Benjamin Rolles  1   2 , Martin Kirschner  1   2 , Florian Holtbernd  3 , Mareike Tometten  1   2 , Tim H Brümmendorf  1   2 , Fabian Beier  1   2
Affiliations
Case Reports

Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)

Patrick P Hess et al. Clin Case Rep. .

Abstract

Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy-induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot-Marie-Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms.

Keywords: Hodgkin; hematology; lymphoma; neurology; neuropathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) CT scan before and (B) after 6 cycles modified BEACOPP
FIGURE 2
FIGURE 2
H&E staining of the right cervical lymph node. (A) 100× magnification, (B) 200× magnification
FIGURE 3
FIGURE 3
EBV positivity of the right cervical lymph node. (A) 20× magnification, (B) 40× magnification. Immunohistochemistry with antibodies against EBV‐latent membrane protein (LMP)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. FitzGerald TJ, Bishop‐Jodoin M. Hodgkin lymphoma: differences in treatment between Europe and the United States/North America: evolving trends in protocol therapy. Clin Med Insights Oncol. 2018;12:1179554918754885. - PMC - PubMed
    1. Borchmann P, Goergen H, Kobe C, et al. PET‐guided treatment in patients with advanced‐stage Hodgkin's lymphoma (HD18): final results of an open‐label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet. 2018;390(10114):2790‐2802. - PubMed
    1. Engert A, Haverkamp H, Kobe C, et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet. 2012;379(9828):1791‐1799. - PubMed
    1. Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res. 2015;97:122‐130. - PubMed
    1. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy‐induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772‐781. - PMC - PubMed

Publication types

LinkOut - more resources